TJM Labs

About TJM Labs

TJM Labs provides AI-driven automation software designed to streamline repetitive operational tasks for pharmacies. The company was founded in June 2024 by Jonathan Adly, who now serves as CEO. Adly, a pharmacist with a PharmD and MBA, spent 15 years working in pharmacies where he identified the need to free talented pharmacists from manual data entry to focus on patient care. This experience directly led to the creation of TJM Labs and its core philosophy. Headquartered in Bear, Delaware, the company targets a wide range of clients, including independent, specialty, compounding, and enterprise pharmacies across the United States and Canada. The business operates on a B2B model, providing its AI agents as a service that integrates directly into existing pharmacy management systems without requiring replacement. This approach allows pharmacies to automate high-volume workflows such as prescription intake and data entry, fax processing, refill management, prior authorization support, and patient communications. One case study noted that a single AI bot could process 4,000 orders daily, leading to significant efficiency gains and annual savings. A key differentiator for TJM Labs is its "Dual-Expert Model™," which pairs a pharmacist with an AI engineer for every implementation. This ensures that the automation is tailored to real-world pharmacy workflows and maintains clinical accuracy and compliance. The company has demonstrated significant growth, raising $100 million in total funding across Series A, A-1, and B rounds within approximately six months. The latest $75 million Series B round was led by Elephant, with participation from Arthur Ventures and Updata Partners. TJM Labs has also expanded its capabilities through the acquisitions of EncoreRx, for data entry automation, and Pharmesol, for voice AI and patient communication, consolidating them into a single platform. As of mid-2026, the company's AI agents are utilized in over 450 pharmacies, processing more than 500,000 tasks daily.